Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Cardinal Therapeutics Inc
Profile last edited on: 11/9/16      CAGE: 55L94      UEI:

Business Identifier: anti-inflammatory compounds for treatment of multiple sclerosis
Year Founded
2008
First Award
2011
Latest Award
2014
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

830 Menlo Avenue Suite 105
Menlo Park, CA 94025
   (650) 283-5816
   N/A
   N/A
Location: Single
Congr. District: 18
County: San Mateo

Public Profile

Cardinal Therapeutics is trying to develop anti-inflammatory compounds from licensed work, along with related technologies from Stanford researchers, that have shown that systemic treatment with beta-amyloid peptides could reduce inflammation in mouse models of multiple sclerosis.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$496,246
Phase II Dollars
$0
Total Awarded
$496,246

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2014 1 NIH $220,449
Project Title: Therapeutic Amyloid Fibrils
2011 1 NIH $275,797
Project Title: Alpha B Crystallin As A Novel Therapeutic For Sirs And Sepsis

Key People / Management

  Hideki Garren -- President

  Jonathan B Rothbard

Company News

There are no news available.